On February 26, Dr Hirsch hosted a conversation with Bill Sibold, Executive Vice President & Head of Sanofi Genzyme, Sanofi, entitled, “The Value of Downstream Innovation—Improving Patient Access to Groundbreaking Therapies.” They discussed the reality that developers of all sizes share the responsibility to help make therapies available, not only to produce them quickly. “Lessons from the real world, how medicines are reaching patients and working—or failing to—can meaningfully influence the early stages of development,” said Dr Hirsch. “Recognizing the potential value, the challenge becomes, how to interpret and apply those lessons to everyone’s benefit.”